title: Is maternal thyrotropin releasing hormone administration safe in the pregnant woman with preeclampsia?
abstract: Maternal intravenous administration of thyrotropin releasing hormone (TRH) is associated with rapid elevations of blood pressure potentially causative of cerebrovascular accidents. We report a case in which peak blood pressure of 220/120 mm Hg was attained from a baseline of 132/80 mm Hg following TRH administration in a preeclamptic patient.
authors.affiliation: Department of Obstetrics and Gynecology, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Tan
authors.forename: C D
authors.initials: CD
authors.lastname: Hsu
authors.forename: S
authors.initials: S
authors.lastname: Marder
authors.forename: J A
authors.initials: JA
authors.lastname: Copel
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D005260:Female; D005325:Fetal Organ Maturity / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007231:Infant, Newborn; D007234:Infant, Premature; D007275:Injections, Intravenous; D008168:Lung / Q000187:drug effects / Q000196:embryology; D011175:Positive-Pressure Respiration; D011225:Pre-Eclampsia / Q000503:physiopathology*; D011247:Pregnancy; D012127:Respiratory Distress Syndrome, Newborn / Q000517:prevention & control; D012449:Safety; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D013973:Thyrotropin-Releasing Hormone